MyFinsight
Home
Blog
About
Net loss
-$92,000K
(19.97%↑ Y/Y)
Crysvita
$54,000K
(55.50%↑ Y/Y)
Dojolvi
$27,000K
(16.34%↑ Y/Y)
Evkeeza
$21,000K
(44.10%↑ Y/Y)
Mepsevii
$10,000K
(20.34%↑ Y/Y)
Loss before income
taxes
-$91,000K
(20.18%↑ Y/Y)
Provision for income taxes
$1,000K
(5.60%↑ Y/Y)
Interest income
$5,000K
(-13.70%↓ Y/Y)
Other income
$1,000K
(-53.27%↓ Y/Y)
Product
$112,000K
(38.58%↑ Y/Y)
Crysvita-Royalty
$102,000K
(19.05%↑ Y/Y)
Loss from operations
-$75,000K
(30.48%↑ Y/Y)
Non-cash interest
expense on liabilities...
$22,000K
(56.68%↑ Y/Y)
Total revenues
$214,000K
(28.53%↑ Y/Y)
Total operating
expenses
$289,000K
(5.33%↑ Y/Y)
Research and development
$167,000K
(1.37%↑ Y/Y)
Selling, general and
administrative
$88,000K
(1.56%↑ Y/Y)
Cost of sales
$34,000K
(47.81%↑ Y/Y)
Back
Back
Income Statement
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)
source: myfinsight.com